Oric Pharmaceuticals (ORIC) presented a Phase 1 dose optimization update for rinzimetostat combined with darolutamide in mCRPC, alongside details of the upcoming Phase 3 trial, Cantor tells investors in a research note. Efficacy appears comparable to competitor mevrometostat from Pfizer (PFE), with Rinzi showing a potentially better safety profile, the firm says, adding thatshares are down 20%-25%, partly due to early treatment discontinuations shown in the swimmer plot, which are similar to mevrometostat’s experience. Cantor has an Overweight rating on Oric shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric selloff on cancer data ‘appears exaggerated,’ says JonesResearch
- Video: Nike stumbles as timeline for recovery pushed out
- Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3
- Closing Bell Movers: Nike slides 9% after Q3 results, soft outlook
- Oric Pharmaceuticals announces rinzimetostat, ORIC-944, program update